Rating Change
Wolfe Research analysts initiated coverage on LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) with a Outperform rating on July 07, 2026.
new coverageNASDAQ:LBRX
Wolfe Research Initiates Coverage on LB Pharmaceuticals Inc Common Stock (LBRX) with Outperform
Rating Change Wolfe Research analysts initiated coverage on LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) with a Outperform rating on July 07, 2026. Market Context LB…
Market Context
LB Pharmaceuticals Inc Common Stock operates in the Healthcare sector. The stock currently trades at $33.41 with a market capitalization of $508.8M.
Analyst coverage from Wolfe Research provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for LB Pharmaceuticals Inc Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for LB Pharmaceuticals Inc Common Stock
Among the 8 most recent ratings: 8 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 07, 2026 | Wolfe Research | Outperform | N/A |
| Apr 27, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 10, 2026 | Craig-Hallum | Buy | N/A |
| Mar 27, 2026 | Stifel | Buy | N/A |
| Dec 11, 2025 | Stifel | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LBRX Stock Page
Frequently Asked Questions
What does a Outperform rating mean for LBRX?
A Outperform rating from Wolfe Research reflects the analyst's outlook on LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LBRX forecast page.